PSI reached an interim enrollment target of 100 randomized patients in a phase III study of a novel biological agent in chronic myelogenous leukemia (CML).
PSI reached an interim enrollment objective of 100 randomized patients in a phase II study of a novel product for the treatment of overactive bladder.
PSI reached an interim enrollment target of 50 randomized patients in a phase III study of a novel dialysis product in chronic kidney disease.
